TIDMGEN
Company Announcement
COPENHAGEN, Denmark; July 06, 2021 --
https://www.globenewswire.com/Tracker?data=yYkPtdndG01Iz72SiZZI5a674bjNiHj_yjWz2is10s0CT9VuNf7IrhPUGcXji2_iGQ6qOGOMlluD9L-91Wn5mA==
Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,974
shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
660 shares at DKK 31.75,
550 shares at DKK 220.40,
9,487 shares at DKK 337.40,
125 shares at DKK 466.20,
1,875 shares at DKK 636.50,
703 shares at DKK 815.50,
6,625 shares at DKK 939.50,
7,128 shares at DKK 962.00,
12,272 shares at DKK 1,032.00,
10 shares at DKK 1,136.00,
2,783 shares at DKK 1,145.00,
934 shares at DKK 1,210.00,
500 shares at DKK 1,233.00,
225 shares at DKK 1,402.00,
372 shares at DKK 1,424.00, and
3,725 shares at DKK 1,432.00.
Proceeds to the company are approximately DKK 42.04 million. The
increase corresponds to approximately 0.07% of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription. The new shares will be listed on Nasdaq
Copenhagen after registration with the Danish Business Authority.
The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No.
1767 of November 27, 2020, it is hereby announced, that the total
nominal value of Genmab A/S' share capital after the capital
increase is DKK 65,668,714 which is made up of 65,668,714 shares of
a nominal value of DKK 1 each, corresponding to 65,668,714
votes.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of patients with cancer. Founded in
1999, Genmab is the creator of multiple approved antibody
therapeutics that are marketed by its partners. The company aims to
create, develop and commercialize differentiated therapies by
leveraging next-generation antibody technologies, expertise in
antibody biology, translational research and data sciences and
strategic partnerships. To create novel therapies, Genmab utilizes
its next-generation antibody technologies, which are the result of
its collaborative company culture and a deep passion for
innovation. Genmab's proprietary pipeline consists of modified
antibody candidates, including bispecific T-cell engagers and
next-generation immune checkpoint modulators, effector function
enhanced antibodies and antibody-drug conjugates. The company is
headquartered in Copenhagen, Denmark with locations in Utrecht, the
Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more
information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=yYkPtdndG01Iz72SiZZI5V5fcm0cSt1cBpG__n-57DDDBVSK_zTzDxU4BszNDVB8doWYo7qQlv_5EwiuNf74BA==
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=cIyQf5LOSq9Vt9AjRUc7g8V6hGccaDHJZ3sGBeUvTvvuVGivmm34eHWmOVl0bPqLZBXDyk7JIfZosXz-Mkaw9g==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=leMXeTlP00EAPUhoarMCsSRQkafmoGuJE2e1s7WMkv1TYlA0D9zVaTr0FXoNOqo8OU7qA03CBKA7TcHgGdiSqg==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=76yuxjEPOrxZDmNVEu1w5Vq3u8QbKQjE-mFyjPf-Jvt6lVabZfSbq9h0VYBvLk0NBc4h0R-qFMl_Gz8YU-cXKQ==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=76yuxjEPOrxZDmNVEu1w5YjnGCNGwfLepMHX2KwA4mt_tJMRSACFnXgQlRdjihkZ8qusaktKS-mXc_a3Vi3eD6yqMmNEWkQFoSB9znQClY4=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 57
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 210706_CA57_Warrant Exercise
https://ml-eu.globenewswire.com/Resource/Download/281a0012-476b-4ce1-8b92-a2d8ad722638
(END) Dow Jones Newswires
July 06, 2021 14:04 ET (18:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2023 to Mar 2024